Graft-versus-host disease.
Combinations of drugs such as methotrexate, cyclosporin A, and prednisone have reduced the incidence of graft-versus-host disease (GVHD) to 20% to 30%. However, GVDH remains a major complication (up to 90%) following allogeneic bone marrow transplantation from unrelated or mismatched donors. GVHD is now understood as a two-step phenomenon: first, the activation of specific cytotoxic T cells and second, the release of several cytokines. Recent treatment modalities, including new immunosuppressors, T-cell depletion, and anticytokine monoclonal antibodies are discussed.
Bron
D
D
Institut Jules Bordet, Free University of Brussels, Belgium.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002648:Child; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D005938:Glucocorticoids / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000276:immunology / Q000401:mortality / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008212:Lymphocyte Depletion; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D015996:Survival Rate; D016176:T-Lymphocyte Subsets / Q000276:immunology; D013792:Thalidomide / Q000627:therapeutic use; D016896:Treatment Outcome
D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D013792:Thalidomide